Cullinan Therapeutics, Inc. (CGEM)
NASDAQ · Healthcare
Cullinan Therapeutics, Inc. Revenue 2020–2022
Cullinan Therapeutics, Inc. annual/quarterly revenue history and growth rate from 2020 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Cullinan Therapeutics, Inc. revenue for the quarter ending September 30, 2022 was 0.
- Cullinan Therapeutics, Inc. revenue for the twelve months ending September 30, 2022 was 0.
- Cullinan Therapeutics, Inc. annual revenue for 2022 was 0, a 100.00% decrease from 2021.
- Cullinan Therapeutics, Inc. annual revenue for 2021 was 18.9 M.
- Cullinan Therapeutics, Inc. annual revenue for 2020 was 0.
Revenue
TRAILING 12 MONTHS · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Cullinan Therapeutics, Inc. (CGEM) — Frequently Asked Questions
Cullinan Therapeutics, Inc. (CGEM) is a publicly traded US company. Explore CGEM's stock price, financial statements, earnings history, margins and key ratios below.
Is CGEM profitable?
In fiscal 2022, Cullinan Therapeutics, Inc. reported net income of $111M.